Avacopan in ANCA-Associated Vasculitis with Severe Kidney Disease (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0658; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The ADVOCATE trial which showed avacopan's non-inferiority to prednisone for remission at 26 weeks and superiority at 52 weeks excluded individuals with an eGFR <15 ml/min/1.73 m2 or those requiring renal replacement therapy (RRT)...Induction regimens included PLEX (39%), rituximab monotherapy (61%), cyclophosphamide (22%), or a combination of both (17%)...Conclusion In this real-world cohort of patients with profound renal impairment treatment with avacopan was characterized by successful glucocorticoid withdrawal and a favorable safety profile and no hepatotoxicity. The observation of clinical remission and liberation from RRT in nearly half of the RRT dependent patients warrants further prospective investigation in this high-risk population."
ANCA Vasculitis • Infectious Disease • Nephrology • Renal Disease • Vasculitis
|
|
Ayeesha Kattubadi; Yara Bilen; Abdallah Sassine Geara; Duvuru Geetha
|